Starton Therapeutics (Starton Therapeutics) Cash-to-Debt : 0.85 (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Starton Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Starton Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2023 was 0.85.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Starton Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Starton Therapeutics's Cash-to-Debt or its related term are showing as below:

STA's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.23
* Ranked among companies with meaningful Cash-to-Debt only.

Starton Therapeutics Cash-to-Debt Historical Data

The historical data trend for Starton Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Starton Therapeutics Cash-to-Debt Chart

Starton Therapeutics Annual Data

Trend

Mar21

Mar22

Mar23

Cash-to-Debt

2.10

0.19

0.09

Starton Therapeutics Quarterly Data
	Mar21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23
Cash-to-Debt	Get a 7-Day Free Trial			0.19	N/A	0.04	0.09	0.85

Competitive Comparison of Starton Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Starton Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Starton Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starton Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Starton Therapeutics's Cash-to-Debt falls into.

Starton Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Starton Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.142	/	(0.161	+	1.451)
	=	0.09

Starton Therapeutics's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.345	/	(0.157	+	1.421)
	=	0.85

Starton Therapeutics (NAS:STA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Starton Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Starton Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Starton Therapeutics (Starton Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 College Road, Suite No.300, Paramus, NJ, USA, 07652

Website

https://www.startontx.com

Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.

Starton Therapeutics (Starton Therapeutics) Headlines

No Headlines